CompletedNCT02953639
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
This study evaluated the safety and effectiveness of Basmisanil for people with schizophrenia.
Medication studyAges 18–50United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Basmisanil for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 36 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: November 30, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 214
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT02953639
- Official title
Show the full official title
A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics
Get this study by email
Recruitment & locations
CompletedLittle Rock · Rogers · Culver City
32 more locations
- Garden Grove
- Glendale
- Long Beach
- National City
- Oakland
- Orange
- Pico Rivera
- San Diego
- Torrance
- New Haven
- Largo
- Lauderhill
- Maitland
- Miami
- North Miami
- Decatur
- Hoffman Estates
- Anderson
- Shreveport
- Gaithersburg
- Boston
- St Louis
- Berlin
- Cedarhurst
- New York
- Rochester
- Canton
- Cleveland
- Dayton
- Garland
- Irving
- Bellevue
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Basmisanil for people with schizophrenia.
Who is behind this study?
The study sponsor is Hoffmann-La Roche.
Did this study involve medication?
Yes. The study involved medication, including Basmisanil and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia